Last updated: March 9, 2023
Sponsor: Lawson Health Research Institute
Overall Status: Active - Recruiting
Phase
4
Condition
Chest Pain
Heart Failure
Hyponatremia
Treatment
N/AClinical Study ID
NCT05594823
REDA ID: 12724
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Diagnosis of heart failure, either reduced (Left ventricular ejection fraction [LVEF] ≤ 40%) or preserved (LVEF > 40%) ejection fraction as measured by echocardiographyperformed within the last 2 months
- Prescribed and tolerating furosemide with a minimum daily dose of 40mg oral daily
- New York Heart Association (NYHA) Class II or higher symptoms
- NT-proBNP cutoff of ≥ 1000 pg/mL performed within 30 days prior to randomization
- Age > 18 years
- English speaking
- Access to a scale and ability to weigh themselves daily and reliable telephone access
Exclusion
Exclusion Criteria:
- Myocardial infarction, coronary artery bypass graft surgery, stent insertion and/orangioplasty within 14 days
- Pregnancy
- Inability to follow directions and self-monitor as part of a flexible diuretic regimenas discerned by the clinician
- Allergic reaction to loop diuretics
- Unable to provide informed consent
Study Design
Total Participants: 30
Study Start date:
January 03, 2023
Estimated Completion Date:
July 31, 2023
Connect with a study center
St. Joseph's Health Care
London, Ontario N6A 4V2
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.